This article is more than 5 years old. Information may no longer be current.
Monoclonal antibody fails to meet efficacy endpoints for noninfectious uveitis
Secukinumab fell short of primary efficacy endpoints in the treatment of noninfectious uveitis, according to the results of three clinical trials.
Data were culled from the phase 3 SHIELD, INSURE and ENDURE studies. The SHIELD study included 118 patients, the INSURE study included 31 patients, and the ENDURE study included 125 patients.
After a subcutaneous loading phase in each treatment arm, patients received subcutaneous maintenance therapy with secukinumab 300 mg every 2 weeks, secukinumab 300 mg monthly or placebo in the SHIELD study; secukinumab 300 mg every 2 weeks, secukinumab 300 mg monthly, secukinumab 150 mg monthly or placebo in the INSURE study; or secukinumab 300 mg every 2 weeks, secukinumab 300 mg monthly, secukinumab 150 mg monthly or placebo in the ENDURE study.
The secukinumab and placebo groups had similar rates of uveitis recurrence in each study. A reduction in mean total post-baseline immunosuppressive medication scores was associated with secukinumab in the SHIELD study (P = .019). Visual acuity loss was not reported in any treatment group in any study.
The secukinumab groups had slightly higher rates of ocular and non-ocular adverse events than the placebo groups in all three studies.